Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803839 | 0.91 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP2C9HSD17B10MMP1 | |
| SCHEMBL6418597 | 0.86 | EPHX2 (0.35) | ALDH1A1CYP1A2CYP2C9HSD17B10MMP1 | |
| SCHEMBL6898652 | 0.84 | ALDH1A1 (0.37) | ALDH1A1CYP1A2CYP2C9HSD17B10MMP1 | |
| SCHEMBL6898655 | 0.84 | ALDH1A1 (0.37) | ALDH1A1CYP1A2CYP2C9HSD17B10MMP1 | |
| SCHEMBL2053129 | 0.82 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP2C9MMP1KMT2A | |
| SCHEMBL27750685 | 0.81 | ALDH1A1 (0.38) | ALDH1A1HSD17B10POLBKMT2A | |
| SCHEMBL7795166 | 0.80 | EPHX2 (0.38) | ALDH1A1CYP1A2CYP2C9POLBKMT2A | |
| SCHEMBL6420476 | 0.79 | HSD17B10 (0.43) | ALDH1A1CYP1A2CYP2C9HSD17B10MMP1 | |
| SCHEMBL2784963 | 0.78 | MMP1 (0.42) | ALDH1A1CYP1A2CYP2C9HSD17B10MMP1 | |
| SCHEMBL4638135 | 0.78 | CYP1A2 (0.39) | ALDH1A1CYP1A2CYP2C9HSD17B10KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0957917-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6825188-B2 | MORE POTENT INHIBITORS OF THE VITRONECTIN RECEPTOR THAN THE FIBRINOGEN | SMITHKLINE BEECHAM CORPORATION | 2004-11-30 | — | — | US | disclosed |
| EP-1017387-A4 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORP (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040082559-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| US-20030216377-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2003-11-20 | — | — | US | disclosed |
| EP-0946180-A4 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030125317-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-20030087894-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
| US-20020128257-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-20020123487-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-09-05 | — | — | US | disclosed |
| US-20020040136-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-04-04 | — | — | US | disclosed |
| US-20020032187-A1 | Method for stimulating bone formation | SMITHKLINE BEECHAM CORPORATION | 2002-03-14 | — | — | US | disclosed |
| US-20020019387-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-02-14 | — | — | US | disclosed |
| US-20010014737-A1 | Vitronectin receptor antagonist | HEERDING DIRK (US) | 2001-08-16 | — | — | US | disclosed |
| EP-1023073-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-02 | — | — | EP | disclosed |
| EP-1017387-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0946180-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999015178-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999015170-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998015278-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040136-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ALDH1A1 3234/4885CYP1A2 3567/4885CYP2C9 3317/4885 |
| US-20030087894-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ALDH1A1 3234/4885CYP1A2 3567/4885CYP2C9 3317/4885 |
| US-20020128257-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ALDH1A1 3234/4885CYP1A2 3567/4885CYP2C9 3317/4885 |
| US-20040082559-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ALDH1A1 3956/4885CYP1A2 2551/4885CYP2C9 3226/4885 |
| US-20030216377-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ALDH1A1 3234/4885CYP1A2 3567/4885CYP2C9 3317/4885 |
| US-20020123487-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ALDH1A1 3234/4885CYP1A2 3567/4885CYP2C9 3317/4885 |
| US-20010014737-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ALDH1A1 3234/4885CYP1A2 3567/4885CYP2C9 3317/4885 |
| US-20020019387-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | ALDH1A1 3234/4885CYP1A2 3567/4885CYP2C9 3317/4885 |
| US-20020032187-A1 | Method for stimulating bone formation | BMP2, BMP4, SOST | ALDH1A1 2599/4885CYP1A2 4457/4885CYP2C9 4808/4885 |
| US-20030125317-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ALDH1A1 3956/4885CYP1A2 2551/4885CYP2C9 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.